The following video is from Monday's Investor Beat, in which host Alison Southwick and Motley Fool analysts Matt Koppenheffer and Matt Argersinger dissect the hardest-hitting investing stories of the day.
Biotech giant Amgen announced today that it's acquiring Onyx Pharmaceuticals for $10.4 billion. In our lead story on Investor Beat, our two Matts discuss the acquisition and look at whether M&A in general is good news for investors.
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article The Biggest Biotech Gets Even Bigger originally appeared on Fool.com.Alison Southwick, Matt Koppenheffer, Matthew Argersinger, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.